Skip to main content

Simon Schwartz Navarro

Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools.

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Cap de Secció
Bioquímica
Cross-departmental services

Simon Schwartz Navarro

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Cap de Secció
Bioquímica
Cross-departmental services

Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools.

Currently acting as Strategy director of biobanking and bioresources at Vall d'hebron Campus. President of the European Society of Nanomedicine and Executive Board member of the International Society of Nanomedicine. Former director general of the Blood and Tissue Banc of Catalonia. Former director of CIBBIM-Nanomedicine. Former scientific associate director of CIBER-BBN and coordinator of technology transfer. Former director assistance of translational research at VHIR. H-index of 40, with more that 115 high impact publications and 17 transferred patents. Co-founder of 3 biotech companies (i.e, Bsure Medical ltd). Science Advisor of the European Nanomedicine Characterization Laboratory (EU-NCL). Member of the editorial Board of Precision Nanomedicine, J. Nanotechnology and of J. of Nanotheranostics. Former editorial Board member of Eur. J. Nanomedicine and Nanomedicine-NBM.

Projects

Inestabilitat genòmica i mitocondrial en càncer

IP: Simon Schwartz Navarro
Collaborators: Eloy Espín Basany
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 8200
Reference: 2003 XT 00096
Duration: 01/01/2004 - 31/12/2005

Vías moleculares de respuesta genotóxica al tratamiento quimio- y radioterápico tumoral. Detección de nuevos implicados.

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 1393.2
Reference: BF03/00595
Duration: 01/01/2004 - 30/11/2007

Inestabilitat genòmica i mitocondrial en càncer

IP: Simon Schwartz Navarro
Collaborators: Eloy Espín Basany
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 6010.12
Reference: 2001XT 00069
Duration: 05/02/2002 - 19/02/2004

Mutaciones somáticas mitocondriales en tumores gástricos y su asociación con el pronóstico tumoral. Dinámica mutacional de heteroplasmias en la línea colorectal inestable DLD-1.

IP: Simon Schwartz Navarro
Collaborators: José Manuel Pena Ezquerra, Jordi Giralt López de Sagred, Manuel Armengol Carrasco, Eloy Espín Basany
Funding agency: Instituto de Salud Carlos III
Funding: 112125
Reference: PI020295
Duration: 06/11/2002 - 06/11/2005

Related news

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.

Related professionals

Laura González Mora

Laura González Mora

Administrative Assistant
Communication Unit
Communication Area
Read more
Luca Bollo

Luca Bollo

Predoctoral researcher
Clinical Neuroimmunology
Read more
Alvaro Domingo Madrid Aris

Alvaro Domingo Madrid Aris

Kidney Physiopathology
Read more
Estela Ariza Moral

Estela Ariza Moral

Statistics and Bioinformatics Unit (UEB)
Preclinical Core Facilities
Core Facilities Area
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.